Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-08-08
2006-08-08
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07087592
ABSTRACT:
2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.
REFERENCES:
patent: 2584271 (1952-02-01), Huffman
patent: 2846453 (1958-08-01), Hoehn
patent: 3166577 (1965-01-01), Ringold et al.
patent: 3410879 (1968-11-01), Smith et al.
patent: 3470218 (1969-09-01), Farah
patent: 3492321 (1970-01-01), Crabbe
patent: 3496272 (1970-02-01), Kruger
patent: 3562260 (1971-02-01), De Ruggieri et al.
patent: 3956348 (1976-05-01), Hilscher
patent: 4172132 (1979-10-01), Draper et al.
patent: 4212864 (1980-07-01), Tax
patent: 4307086 (1981-12-01), Tax
patent: 4444767 (1984-04-01), Torelli et al.
patent: 4522758 (1985-06-01), Ward et al.
patent: 4552758 (1985-11-01), Murphy et al.
patent: 4634705 (1987-01-01), DeBernardis et al.
patent: 4743597 (1988-05-01), Javitt et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5504074 (1996-04-01), D'Amato et al.
patent: 5521168 (1996-05-01), Clark
patent: 5621124 (1997-04-01), Seilz et al.
patent: 5629327 (1997-05-01), D'Amato
patent: 5629340 (1997-05-01), Kuwano et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5643900 (1997-07-01), Fotsis et al.
patent: 5646136 (1997-07-01), Petrow
patent: 5661143 (1997-08-01), D'Amato et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
patent: 5763432 (1998-06-01), Tanabe et al.
patent: 5776704 (1998-07-01), O'Reilly et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5837682 (1998-11-01), O'Reilly
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5861372 (1999-01-01), Folkman et al.
patent: 5885795 (1999-03-01), O'Reilly et al.
patent: 5892069 (1999-04-01), D'Amato et al.
patent: 5919459 (1999-07-01), Nacy et al.
patent: 5958892 (1999-09-01), Mukhopadhyay et al.
patent: 6011023 (2000-01-01), Clark et al.
patent: 6046186 (2000-04-01), Tanabe et al.
patent: 6051726 (2000-04-01), Sachdeva et al.
patent: 6054598 (2000-04-01), Sachdeva et al.
patent: 6136992 (2000-10-01), Ram et al.
patent: 6200966 (2001-03-01), Stewart
patent: 6239123 (2001-05-01), Green et al.
patent: 6284789 (2001-09-01), LaLonde et al.
patent: 6346510 (2002-02-01), O'Reilly et al.
patent: 6399773 (2002-06-01), Liu et al.
patent: 6410029 (2002-06-01), Mukhopadhyay et al.
patent: 6413513 (2002-07-01), Holaday
patent: 6514971 (2003-02-01), Thomas et al.
patent: 6528676 (2003-03-01), D'Amato et al.
patent: 6605622 (2003-08-01), Green et al.
patent: 6723858 (2004-04-01), D'Amato et al.
patent: 6730665 (2004-05-01), Maran et al.
patent: 6908910 (2005-06-01), D'Amato et al.
patent: 2002/0002294 (2002-01-01), D'Amato et al.
patent: 2002/0165212 (2002-11-01), D'Amato et al.
patent: 2003/0027803 (2003-02-01), Slaga et al.
patent: 2003/0096800 (2003-05-01), D'Amato et al.
patent: 2003/0236408 (2003-12-01), D'Amato et al.
patent: 2004/0072813 (2004-04-01), D'Amato et al.
patent: 2004/0214807 (2004-10-01), D'Amato et al.
patent: 2005/0020555 (2005-01-01), D'Amato et al.
patent: 0166937 (1986-08-01), None
patent: 0657175 (1995-06-01), None
patent: 857080 (1960-12-01), None
patent: 857081 (1960-12-01), None
patent: 1570597 (1980-07-01), None
patent: 39-5480 (1939-04-01), None
patent: 41 000100 (1966-01-01), None
patent: 42-928 (1967-01-01), None
patent: 58-131978 (1983-08-01), None
patent: 63090763 (1988-04-01), None
patent: 63-119500 (1988-05-01), None
patent: 09316000 (1997-09-01), None
patent: 11-209322 (1999-08-01), None
patent: 1240038 (1996-10-01), None
patent: WO 87/02367 (1987-04-01), None
patent: WO 88/08002 (1988-10-01), None
patent: WO 90/15816 (1990-12-01), None
patent: WO 93/03729 (1993-03-01), None
patent: WO 93/19746 (1993-10-01), None
patent: WO 95/04535 (1995-02-01), None
patent: WO 98/32763 (1998-07-01), None
patent: WO 98/40398 (1998-09-01), None
patent: WO 99/01142 (1999-01-01), None
patent: WO 99/22728 (1999-05-01), None
patent: WO 99/33858 (1999-07-01), None
patent: WO 99/33859 (1999-07-01), None
patent: WO 99/35150 (1999-07-01), None
patent: WO 99/45018 (1999-09-01), None
patent: WO 00/07576 (2000-02-01), None
patent: WO 00/10552 (2000-03-01), None
patent: WO 00/66095 (2000-11-01), None
patent: WO 00/68246 (2000-11-01), None
Nambara, T., et al., “Studies on Steroid Conjugates. III. New Syntheses of 2-Methoxyestrogens”Chem. Pharm. Bull., vol. 18, No. 3, pp. 474-480 (1970).
Napolitano, et al., “11 Beta-Substituted Estradiol Derivatives. 2. Potential Carbon-11-and Inodine-Labeled Probes for the Estrogen Receptor”,J. Med. Chem., vol. 38, No. 14, pp. 2774-2779 (Jul. 7, 1995) (Abstract Only).
Nishigaki, et al., “Anti-Proliferative Effect of 2-Methoxyestradiol on Cultured Smooth Muscle Cells from Rabbit Aorta”,Atherosclerosis, vol. 113, pp. 167-170 (1995).
Numazawa M. et al., “Efficient Synthesis of 2-Methoxy- and 4-Methoxy-Estrogens”J. Chem. Soc., pp. 533-534 (1983).
Oppolzer, et al., “177.The Enantioslective Synthesis of (+)-Estradiol from 1,3-Dihydrobenzo[c]thiophene-2,2-dioxide by Successive Thermal SO2-Extrusion and Cycloaddition Reactions”,Helvetica Chimica Acta, vol. 63, pp. 1703-1707 (1980).
Parthasarathy, et al., “Antioxidant: A New Role for RU-486 and Related Compounds”,J. Clin. Invest., vol. 94, No. 5, pp. 1990-1995 (1994) (Abstract Only).
Paull, et al., “Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-assisted Evaluation of Differential Cytotoxicity Data”,Cancer Research, vol. 52, pp. 3892-3900 (Jul. 15, 1992).
Poli et al., “Tumor Necrosis Factor α Functions in an Autocrine Manner in the Induction of Human Immunodeficiency Virus Expression”,Proc. Natl. Acad. Sci. USA, vol. 87, pp. 782-785 (Jan. 1990).
Rao, et al., “Structural Specificity of Estrogens in the Induction of Mitotic Chromatid Non-Disjunction in Hela Cells”,Experimental Cell Research, vol. 48, pp. 71-81 (1967).
Rao, et al., “A Novel, Two-Step Synthesis of 2-Methoxyestadiol”Synthesis, pp. 168-169 (Mar. 1977).
Ravindra, R., “Effect of Estradiol on thein vitroAssembly of Rat Brain Tubulin”,J. Indian Inst. Sci., vol. 64, No. 3, pp. 27-35 (1983).
Sakakibara et al., “Effects of Diethylstilbestrol and its Methyl Ethers on Aneuploidy Induction and Microtubule Distribution in Chinese Hamster V79 cells”,Mutation Research, vol. 263, pp. 269-276 (1991).
Sato et al., “Effect of Estradiol and Ethynylestradiol on Microtubule Distribution in Chinese Hamster V79 Cells”,Chem. Pharm. Bull., vol. 40, No. 1, pp. 182-184 (1992).
Sato et al., “Disruptive Effect of Diethylstillbestrol on Microtubules”,Gann, vol. 75, pp. 1046-1048 (1984).
Adams, E.F. et al., “Steroidal regulation of oestradiol-17B dehydrogenase activity of the human breast cancer cell line MCF-7”,Journal of Endocrinology, vol. 188, pp. 149-154 (Jul. 1988).
Aizu-Yokota, et al., “Natural Estrogens Induce Modulation of Microtubules in Chinese Hamster V79 Cells in Culture”,Cancer Research, vol. 55, pp. 1863-1868 (May 1, 1995).
Attalla, et al., “2-Methoxyestradiol Arrests Cells in Mitosis without Depolymerizing Tubulin”,Biochem. and Biophys. Resch. Comm., vol. 228, pp. 467-473 (1996).
Ayala, et al. “The Induction of Accelerated Thymic Programmed Cell Death During Polymicrobial Sepsis: Control by Corticosteroids but not Tumor Necrosis Factor”,Shock, vol. 3, No. 4, pp. 259-267 (Apr. 1995) (Abstract Only).
Banik, et al., “Orally Active Long-Acting Es
Agoston Gregory E.
Shah Jamshed H.
Treston Anthony M.
Badio Barbara P.
Entre Med, Inc.
Kilpatrick & Stockton LLP
LandOfFree
Compositions comprising purified 2-methoxyestradiol and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions comprising purified 2-methoxyestradiol and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions comprising purified 2-methoxyestradiol and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3642812